AKT1 and prostate cancer: The loss of PTEN, resulting in tumorigenesis or drug resistance due to a hyperactivation of the PI3K/Akt/mTOR pathway, is the second most common genomic aberration in advanced prostate cancer after the androgen-receptor (AR) alterations [38].